Development and study of specific Kir channel inhibitors
特异性Kir通道抑制剂的开发与研究
基本信息
- 批准号:7586210
- 负责人:
- 金额:$ 22.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-04-01 至 2011-02-28
- 项目状态:已结题
- 来源:
- 关键词:Action PotentialsAffectAffinityAnimalsAnthelminticsAnti-Arrhythmia AgentsArrhythmiaBeesBiochemistryCardiacChimera organismComplementDevelopmentElectrolyte BalanceElectrophysiology (science)EngineeringEvolutionExhibitsFutureGene DeletionGeneticGlutamatesGoalsHeart DiseasesHereditary DiseaseHoneyImmunoglobulin Variable RegionIndividualIon ChannelKidneyKir2.1 channelLengthLibrariesMedicineMolecular BiologyMusMutateMutationOutcomePerceptionPhysiologicalPhysiologyPiperazinesPlayPolyaminesPotassium ChannelPreparationPropertyProteinsRefractoryResearchResearch DesignResearch PersonnelResolutionRoleSafetyShapesSpecificityStructureSyndromeSystemTestingTherapeuticTherapeutic AgentsTissuesToxinUncertaintybasecell typeheart electrical activityinhibitor/antagonistmutantprogramsprototypetertiapintherapeutic target
项目摘要
The long-term goals of our research are to develop inhibitors specifically targeting individual subtypes of
ion channels, to determine inhibitor-channel interaction mechanisms, and to use the inhibitors to examine
channel physiology and demonstrate certain therapeutic concepts. Since inward-rectifier K+ (Kir) channels
play many vital physiological roles and represent increasingly important therapeutic targets, subtype-specific
Kir channel inhibitors are experimentally and therapeutically valuable. The studies proposed below will be
carried out with a combined approach of electrophysiology, biochemistry, and molecular biology.
Previously, we discovered that a 21-residue honey bee toxin, tertiapin (TPN), inhibits renal Kir1.1 and
cardiac Kir3.1/3.4 channels with nanomolar affinity. In Aim#1, we will create inhibitors specific for Kir1.1 or
Kir3.1/3.4. Our preliminary studies have not only identified the channel sequence that will allow the selective
targeting of various Kir subtypes but also established the prototype for such a subtype-specific inhibitor. The
resulting specific inhibitors can be used in future studies to help prove the concept of new classes of
medicine for treating certain cardiac diseases.
Additionally, we found that piperazine - a very safe and inexpensive anthelmintic which has been shown
to be anti-arrhythmic in some animal preparations - selectively inhibits strongly rectifying Kir channels such
as Kir 2.1. The selectivity and safety of piperazine make it (or its derivatives) a promising candidate agent
for treating certain cardiac arrhythmias. Because of this potential therapeutic value we will, in Aim#2,
investigate the mechanisms by which piperazine interacts with the channel through a combination of
energetic and structural studies. Furthermore, as the first step toward proving the concept, we will
demonstrate that certain blocking properties of piperazine can be exploited for treating a form of short QT
syndrome caused by a mutation in Kir2.1.
The outcome of the proposed studies will significantly enhance our ability to decipher the physiological
functions of Kir channels in a given cell type or tissue, and help in the development of effective therapeutic
agents.
我们研究的长期目标是开发专门针对个别亚型的抑制剂。
离子通道,以确定抑制剂-通道相互作用机制,并使用抑制剂检查
引导生理学,并展示特定的治疗概念。由于内向整流K+(KIR)通道
发挥许多重要的生理作用,并代表着越来越重要的治疗靶点,亚型特定
KIR通道抑制剂具有实验和治疗价值。以下建议的研究将是
采用电生理学、生物化学和分子生物学相结合的方法进行。
此前,我们发现一种21个残基的蜜蜂毒素,Tertiapin(TPN),抑制肾脏Kir1.1和
心肌Kir3.1/3.4通道具有纳摩尔亲和力。在目标1中,我们将创建针对Kir1.1或
Kir3.1/3.4。我们的初步研究不仅确定了允许选择性地
靶向不同的KIR亚型,也建立了这种亚型特异性抑制剂的原型。这个
由此产生的特定抑制剂可用于未来的研究,以帮助证明新的类别的概念
治疗某些心脏病的药物。
此外,我们发现哌嗪是一种非常安全和廉价的驱虫剂,已经被证明
在某些动物制剂中具有抗心律失常作用--选择性地抑制强整流性KIR通道
作为KIR 2.1。哌嗪的选择性和安全性使其(或其衍生物)成为一种很有前途的候选药物
用于治疗某些心律失常。由于这种潜在的治疗价值,我们将在目标2中,
研究哌嗪与通道相互作用的机制,通过结合
精力充沛和结构研究。此外,作为证明这一概念的第一步,我们将
证明可以利用哌嗪的某些阻断特性来治疗一种形式的短QT
由Kir2.1基因突变引起的综合征。
拟议的研究结果将显著提高我们破译生理学的能力
KIR通道在特定细胞类型或组织中的功能,并有助于开发有效的治疗方法
探员们。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Characterization of inward-rectifier K+ channel inhibition by antiarrhythmic piperazine.
抗心律失常哌嗪抑制内向整流 K 通道的特性。
- DOI:10.1021/bi0483099
- 发表时间:2004
- 期刊:
- 影响因子:0
- 作者:Xu,Yanping;Lu,Zhe
- 通讯作者:Lu,Zhe
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ZHE LU其他文献
ZHE LU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ZHE LU', 18)}}的其他基金
Development of novel means to stimulate Ca2+-dependent exocytotic secretion
开发刺激 Ca2 依赖性胞吐分泌的新方法
- 批准号:
9155329 - 财政年份:2016
- 资助金额:
$ 22.74万 - 项目类别:
Development and study of specific Kir channel inhibitors
特异性Kir通道抑制剂的开发与研究
- 批准号:
7092755 - 财政年份:2001
- 资助金额:
$ 22.74万 - 项目类别:
Development /use of peptidic inhibitors for Kir channels
Kir 通道肽抑制剂的开发/使用
- 批准号:
6727515 - 财政年份:2001
- 资助金额:
$ 22.74万 - 项目类别:
Development /use of peptidic inhibitors for Kir channels
Kir 通道肽抑制剂的开发/使用
- 批准号:
6520330 - 财政年份:2001
- 资助金额:
$ 22.74万 - 项目类别:
Development and study of specific Kir channel inhibitors
特异性Kir通道抑制剂的开发与研究
- 批准号:
7186629 - 财政年份:2001
- 资助金额:
$ 22.74万 - 项目类别:
Development /use of peptidic inhibitors for Kir channels
Kir 通道肽抑制剂的开发/使用
- 批准号:
6326870 - 财政年份:2001
- 资助金额:
$ 22.74万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 22.74万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 22.74万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 22.74万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 22.74万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 22.74万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 22.74万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 22.74万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 22.74万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 22.74万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 22.74万 - 项目类别:
Grant-in-Aid for Early-Career Scientists